494

# CHAPTER 7890 MINNESOTA RACING COMMISSION HORSE MEDICATION

7890.0100 DEFINITIONS. 7890.0140 BLEEDERS.

7890.0110 MEDICATIONS AND PRACTICES PROHIBITED. 7890.0160 RESPONSIBILITY OF VETERINARIAN.

7890.0120 REPORTING PROCEDURES.

# **7890.0100 DEFINITIONS.**

[For text of subps 1 to 3a, see M.R.]

Subp. 3b. **Bicarbonate loading.** "Bicarbonate loading" means the use of an alkalinizing agent either through a nasogastric tube or by other means that elevates the plasma or serum TCO<sub>2</sub>.

Subp. 3c. **Biological product.** "Biological product" means any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment, or cure of diseases or injuries.

[For text of subps 4 to 10a, see M.R.]

Subp. 10b. **Feed contaminant.** Substances in equine feed arising from contamination during cultivation, processing or treatment, storage, or transportation.

Subp. 10c. **Flunixin meglumine.** "Flunixin meglumine" is a nonsteroidal anti-inflammatory drug with the chemical name 3-pyridine-carboxylic acid.

Subp. 10d. **Furosemide.** "Furosemide" means 4-chloro-N-furfuryl-5-sulfamoylan-thranilic acid.

Subp. 10e. **Growth factor.** "Growth factor" means a substance that promotes cellular growth.

Subp. 10f. **Hemopure**. "Hemopure®" is a chemically stabilized bovine cross-linked hemoglobin that carries oxygen to tissues. Chemically it is hemoglobin glutamer-250 (bovine) or HBOC-201.

[For text of subps 11 to 12, see M.R.]

Subp. 13. **Medication.** "Medication" is a substance, compound, or element, or combination thereof, which is or can be administered to a horse for the purpose of preventing, curing, or alleviating the effects of any disease, condition, ailment, or infirmity, or symptom thereof, or for altering in any way the behavior, attitude, temperament, or performance of a horse, including athletic performance. The term medication includes all analgesics, anesthetics, depressants, narcotics, stimulants, tranquilizers, and other classifications of medications. Nothing herein shall be deemed to include:

[For text of item A, see M.R.]

- B. Furosemide, provided, however, that it is administered pursuant to the provisions of part 7890.0140, subpart 7a, and further provided that: the specific gravity of the post-race urine sample is not 1.010 or below or, if the specific gravity is 1.010 or below or a urine sample is unavailable for testing, the concentration of Furosemide must not exceed 100 nanograms per milliliter of serum or plasma in the post-race blood sample.
- C. Topical applications, such as antiseptics, ointments, salves, leg rubs, and leg paints which may contain antibiotics (excluding procaine, penicillin, and chloramphenicol) but which shall not contain ethanol, benzocaine, DMSO, lidocane, steroids, or other medications.

[For text of item D, see M.R.]
[For text of subp 13a, see M.R.]

495

- Subp. 13b. **Milkshaking.** "Milkshaking" (to include bicarbonate loading) means the use of an alkalinizing agent administered through a nasogastric tube or by any other means that changes the normal physiological state of a horse through elevation of plasma or serum TCO<sub>2</sub>.
- Subp. 13c. **Measurement uncertainty (MU).** "Measurement uncertainty" means a value (with units of concentration) that is determined experimentally and characterizes the variability of the analytical process. It is used to eliminate all reasonable variability originating from the measurement process. It is a property of the method used and unique to each laboratory unless measures have been taken to standardize between laboratories.

Subp. 16a. TCO<sub>2</sub>. "TCO<sub>2</sub>" means the total concentration of all forms of carbon dioxide in the sample including bicarbonate and carbonate as well as dissolved CO<sub>3</sub>.

[For text of subps 17 to 21, see M.R.]

Statutory Authority: MS s 240.23

History: 34 SR 1135; 35 SR 375; 35 SR 627

# 7890.0110 MEDICATIONS AND PRACTICES PROHIBITED.

[For text of subps 1 and 2, see M.R.]

- Subp. 3. Extracorporeal shock wave therapy or radial pulse wave therapy. The use of extracorporeal shock wave therapy or radial pulse wave therapy shall not be permitted unless the following conditions are met:
- A. any treated horse shall not be permitted to race for a minimum of ten days following treatment with day one being the first day of treatment;

Subp. 4. **Blood doping agents.** The possession or use of blood doping agents by any person, including but not limited to the following blood doping agents, on the premises of a facility under the jurisdiction of the commission is forbidden:

[For text of items A to D, see M.R.] [For text of subps 5 to 7, see M.R.]

- Subp. 7a. Androgenic-anabolic steroids (AAS). No Androgenic-anabolic steroids (AAS) shall be permitted in test samples collected from racing horses except for residues of the major metabolite of stanozolol, nandrolone, and naturally occurring substances boldenone and testosterone at concentrations less than the indicated thresholds. Concentrations of these AAS shall not exceed the following plasma or serum thresholds for unchanged (i.e. not conjugated) substance or urine threshold concentrations for total (i.e., free drug or metabolite and drug or metabolite liberated from its conjugates):
- A. Stanozolol 1 ng/ml of total 16 $\beta$ -hydroxystanozolol (metabolite of stanozolol) in urine of all horses regardless of sex; or 25 pg/ml of stanozolol in plasma or serum of all horses regardless of sex.
- B. Boldenone 15 ng/ml of total boldenone in urine of male horses other than geldings; or 25 pg/ml of boldenone in plasma or serum of all horses regardless of sex.

## C. Nandrolone:

- (1) in geldings 1 ng/ml total nandrolone in urine or 25 pg/ml of nandrolone in plasma or serum;
- (2) in fillies and mares 1 ng/ml total nandrolone in urine or 25 pg/ml of nandrolone in plasma or serum; and
- (3) in male horses other than geldings 45 ng/ml of metabolite,  $5\alpha$ -oestrane-  $3\beta$ ,  $17\alpha$ -diol in urine.

496

#### D. Testosterone:

- (1) in geldings 20 ng/ml total testosterone in urine or 25 pg/ml of testosterone in plasma or serum;
- (2) in fillies and mares 55 ng/ml total testosterone in urine or 25 pg/ml of testosterone in plasma or serum;
- (3) in fillies and mares that are confirmed at the time of racing as being pregnant, testosterone is not regulated; and
- (4) in male horses other than geldings testosterone is not regulated under this rule.

All other AAS are prohibited in racing horses.

The sex of all horses shall be identified on all samples sent to the laboratory. Any horse to which one of these AAS has been administered in order to assist in the recovery from an illness or injury may be placed on the veterinarian's list in order to monitor the concentration of the drug or metabolite in urine. After the concentration has fallen below the designated threshold for the administered AAS, the horse is eligible to be removed from the list.

[For text of subp 8, see M.R.]

- Subp. 9. **Feed contaminants.** No feed contaminants other than those listed below shall be allowed in the test sample of a horse. Levels shall not exceed:
  - A. atropine: 10 ng/ml in urine;
  - B. benzoylecgonine (major urine metabolite of cocaine): 50 ng/ml in urine;
  - C. caffeine: 100 ng/ml in urine;
  - D. morphine glucuronides: 50 ng/ml in urine; or
  - E. theobromine: 2,000 ng/ml in urine.

**Statutory Authority:** *MS s 240.23* **History:** *35 SR 375; 35 SR 627* 

## 7890.0120 REPORTING PROCEDURES.

Subpart 1. **Veterinarians must keep records.** Veterinarians must submit daily to the commission veterinarian, in writing on a prescribed form, a report of all horses treated. The form shall contain the date and time, name of horse treated, trainer of horse, any medications, drugs, substances (as provided in part 7890.0100, subpart 13, items A to D), or procedures prescribed, administered, dispensed, or performed for horses registered at a current race meeting, and any other information requested by the commission veterinarian. The form must be filed by the treating veterinarian not later than post time of the race for which the horse is entered. The form shall be signed by the treating veterinarian. The form is considered private and its content shall not be disclosed except in the course of an investigation of a possible violation of chapters 7869 to 7899, or in a proceeding before the stewards or commission, or to the trainer or owner of record at the time of treatment. A timely and accurate filing of the form that is consistent with the analytical results of a positive test may be used as a mitigating factor in determining the nature and extent, if any, of a rules violation.

- Subp. 2. Administration of NSAIDs to be reported. If a horse is to race with a permitted NSAID in its system, the trainer or other representative shall be responsible for legibly and clearly marking the information on the entry blank for each race in which the horse shall use a permitted NSAID. Changes made after the time of entry must be submitted on the prescribed form to the commission veterinarian no later than scratch time. The specific NSAID to be used must be declared on the entry blank.
- Subp. 3. **Administration of furosemide to be reported.** If a horse is to race with furosemide in its system, the trainer or other representative shall be responsible for legibly

#### **HORSE MEDICATION 7890.0160**

and clearly marking the information on the entry blank for each race the horse shall be entered in.

**Statutory Authority:** *MS s 240.23; 240.24* 

History: 34 SR 1135; 35 SR 627

NOTE: Subpart 3 was also added at 34 SR 1135 to read as follows:

"Subp. 3. Administration of furosemide to be reported. If a horse is to race with a permitted level of furosemide in its system, the trainer is responsible for legibly and clearly marking this information on the entry blank for each race in which the horse shall use a permitted level of furosemide."

### 7890.0140 BLEEDERS.

[For text of subps 1 to 3, see M.R.]

Subp. 4. **Horses placed on bleeder list.** Bleeders shall be placed on a bleeder list and the list shall be kept in the commission veterinarian's office. Horses certified as having bled in Minnesota shall also be placed on the veterinarian's list at the time of the observed bleeding and shall be ineligible to be entered in a race pursuant to subpart 5.

[For text of subp 5, see M.R.]

Subp. 6. **Furosemide may be permitted.** A horse is eligible to race with furosemide if the licensed trainer and licensed veterinarian determine that it would be in the horse's best interests to race with furosemide. Notification using prescribed commission forms must be given to the commission veterinarian no later than scratch time for that day's racing. Once a horse has raced with furosemide, it must continue to race with furosemide in all subsequent races unless a request is made to discontinue the use. If the use of furosemide is discontinued, the horse shall be prohibited from again racing with furosemide unless it is later observed to be bleeding pursuant to subpart 1. Requests for the use of or discontinuance of furosemide must be made to the commission veterinarian by the horse's trainer or assistant trainer on a form prescribed by the commission on or before the day of entry into the race for which the request is made.

[For text of subps 7 to 9, see M.R.]

Subp. 10. **Responsibility of trainer.** The trainer is responsible for ensuring that the horse is available at the appropriate time for its treatment. After having been administered furosemide, the horse shall at all times be in the care, custody, and under the supervision of the trainer or a licensed person assigned by the trainer. The horse must remain in its own stall until it is taken to the paddock to be saddled or harnessed for a race. It shall not be handled by anyone other than the trainer, the owner, or the employees listed on the trainer's signed statement. If emergency veterinary attention becomes necessary, the trainer is responsible for immediately notifying the commission veterinarian of the nature of the need and of the identity of the responding veterinarian. The trainer shall be responsible for the guarding, condition, care, and handling of the horse at all times and ensuring that a handler is present to restrain and serve as a designated witness to the furosemide administration. If no handler is present and the administration time has passed, no furosemide shall be administered and the stewards shall be notified. Trainers are responsible for ensuring that a veterinarian licensed by the commission has agreed to administer furosemide at the designated time.

**Statutory Authority:** MS s 240.23

History: 35 SR 627

# 7890.0160 RESPONSIBILITY OF VETERINARIAN.

No veterinarian may administer a medication, alkalinizing agent, blood doping agent, venom, or substance foreign to the natural horse to any horse that is scheduled to race within 48 hours, except as permitted in part 7890.0100, subpart 13, or in the case of a medical emergency requiring immediate treatment, without the prior permission of the commission veterinarian. No veterinarian may place a nasogastric tube in a horse that is scheduled to race within 48 hours, except in the case of a medical emergency requiring immediate treatment. No veterinarian may enter the stall of or otherwise handle a horse that is scheduled to

497

# **MINNESOTA RULES 2010**

# 7890.0160 HORSE MEDICATION

race on race day, except in the case of a medical emergency requiring immediate treatment without the prior permission of the commission veterinarian. In emergency cases it is the responsibility of the attending veterinarian to notify the commission veterinarian of the nature of the emergency and the exact treatment provided. The notification must be made as soon as practical (within one-half hour of an emergency that occurs during training or racing hours or by 8:00 a.m. on the morning following an emergency which occurred during evening or night hours) and on a form prescribed by the commission. At the request of the commission veterinarian, the veterinarian must provide radiographs, laboratory tests, and results of other diagnostic procedures within 24 hours.

Statutory Authority: MS s 240.23

**History:** 34 SR 1135

498